PedAM
Pediatric Disease Annotations & Medicines
| Disease | priapism |
| Phenotype | C0002895|sickle cell disease |
| Sentences | 11 |
| PubMedID- 25667774 | Generally, reports of lifetime prevalence of priapism in sickle cell disease range from 2 to 35% [90]. |
| PubMedID- 24680796 | We conducted a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of sildenafil by a systematic dosing protocol to prevent recurrent ischemic priapism associated with sickle cell disease. |
| PubMedID- 23767208 | Here we present a case of sickle cell disease with recurrent priapism in a young boy of 16 years of age. |
| PubMedID- 19900167 | Interestingly, sildenafil has been reported to be successful in relieving priapism in patients with sickle cell disease (58). |
| PubMedID- 21219386 | Low-flow (ischaemic) priapism is usually associated with sickle cell disease, haemoglobinopathies, neoplastic syndrome, anticoagulant therapy (heparin and warfarin), psychotropic medication, sildenafil citrate (viagra) or idiopathic causes. |
| PubMedID- 21152267 | priapism is prevalent in patients with sickle cell disease (scd). |
| PubMedID- 21520650 | [acute priapism associated with sickle cell disease in senegal: clinical, therapeutic features and risk factors for erectile dysfunction]. |
| PubMedID- 24363861 | The prevalence of stuttering priapism is greater in patients with sickle cell disease owing to hyperviscosity, increased adhesiveness of the blood to the vascular endothelium, and disrupted vascular homeostasis [8,9]. |
| PubMedID- 21883942 | Potential risks of chronic sildenafil use for priapism in sickle cell disease. |
| PubMedID- 26431892 | Prevention of ischemic priapism in sickle cell disease: sildenafil. |
| PubMedID- 21621085 | Continued action to address the health care administrative concerns of those most commonly affected by priapism, specifically individuals with sickle cell disease, is also appropriate. |
Page: 1